Terms: = Germ cell tumor AND MYC, c-Myc, 4609, ENSG00000136997 AND Clinical Outcome
82 results:
1. TUG1/MAZ/FTH1 Axis Attenuates the Antiglioma Effect of Dihydroartemisinin by Inhibiting Ferroptosis.
Gong H; Gao M; Lin Y; Liu J; Hu Z; Liu J
Oxid Med Cell Longev; 2022; 2022():7843863. PubMed ID: 36164395
[TBL] [Abstract] [Full Text] [Related]
2. High Expression of the Lysosomal Protease Cathepsin D Confers Better Prognosis in Neuroblastoma Patients by Contrasting EGF-Induced Neuroblastoma cell Growth.
Secomandi E; Salwa A; Vidoni C; Ferraresi A; Follo C; Isidoro C
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563171
[TBL] [Abstract] [Full Text] [Related]
3. mycN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis.
Alborzinia H; Flórez AF; Kreth S; Brückner LM; Yildiz U; Gartlgruber M; Odoni DI; Poschet G; Garbowicz K; Shao C; Klein C; Meier J; Zeisberger P; Nadler-Holly M; Ziehm M; Paul F; Burhenne J; Bell E; Shaikhkarami M; Würth R; Stainczyk SA; Wecht EM; Kreth J; Büttner M; Ishaque N; Schlesner M; Nicke B; Stresemann C; Llamazares-Prada M; Reiling JH; Fischer M; Amit I; Selbach M; Herrmann C; Wölfl S; Henrich KO; Höfer T; Trumpp A; Westermann F
Nat Cancer; 2022 Apr; 3(4):471-485. PubMed ID: 35484422
[TBL] [Abstract] [Full Text] [Related]
4. Urinary 3-Methoxytyramine Is a Biomarker for myc Activity in Patients With Neuroblastoma.
Verly IRN; Matser YAH; Leen R; Meinsma R; Fiocco M; Koster J; Volckmann R; Savci-Heijink D; Cangemi G; Barco S; Valentijn LJ; Tytgat GAM; van Kuilenburg ABP
JCO Precis Oncol; 2022 Jan; 6():e2000447. PubMed ID: 35085004
[TBL] [Abstract] [Full Text] [Related]
5. Combined Detection of Copy Number Variations of mycN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma.
Trivedi T; Panchal K; Bhalala N; Trivedi P; Panchal H
World Neurosurg; 2022 Mar; 159():e48-e57. PubMed ID: 34861448
[TBL] [Abstract] [Full Text] [Related]
6. The emerging clinical relevance of genomic profiling in neuroendocrine tumours.
Burak GI; Ozge S; Cem M; Gulgun B; Zeynep DY; Atil B
BMC Cancer; 2021 Mar; 21(1):234. PubMed ID: 33676450
[TBL] [Abstract] [Full Text] [Related]
7. Suppression of ABCE1-Mediated mRNA Translation Limits N-myc-Driven Cancer Progression.
Gao J; Jung M; Mayoh C; Venkat P; Hannan KM; Fletcher JI; Kamili A; Gifford AJ; Kusnadi EP; Pearson RB; Hannan RD; Haber M; Norris MD; Somers K; Henderson MJ
Cancer Res; 2020 Sep; 80(17):3706-3718. PubMed ID: 32651259
[TBL] [Abstract] [Full Text] [Related]
8. De novo evolved gene product NCYM in the pathogenesis and clinical outcome of human neuroblastomas and other cancers.
Suenaga Y; Nakatani K; Nakagawara A
Jpn J Clin Oncol; 2020 Aug; 50(8):839-846. PubMed ID: 32577751
[TBL] [Abstract] [Full Text] [Related]
9. myc transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma.
Wei SJ; Nguyen TH; Yang IH; Mook DG; Makena MR; Verlekar D; Hindle A; Martinez GM; Yang S; Shimada H; Reynolds CP; Kang MH
Cell Death Dis; 2020 May; 11(5):368. PubMed ID: 32409685
[TBL] [Abstract] [Full Text] [Related]
10. HPCAL1 promotes glioblastoma proliferation via activation of Wnt/β-catenin signalling pathway.
Zhang D; Liu X; Xu X; Xu J; Yi Z; Shan B; Liu B
J Cell Mol Med; 2019 May; 23(5):3108-3117. PubMed ID: 30843345
[TBL] [Abstract] [Full Text] [Related]
11.
Zimmerman MW; Liu Y; He S; Durbin AD; Abraham BJ; Easton J; Shao Y; Xu B; Zhu S; Zhang X; Li Z; Weichert-Leahey N; Young RA; Zhang J; Look AT
Cancer Discov; 2018 Mar; 8(3):320-335. PubMed ID: 29284669
[TBL] [Abstract] [Full Text] [Related]
12. PRC2-Mediated Transcriptomic Alterations at the Embryonic Stage Govern tumorigenesis and clinical outcome in mycN-Driven Neuroblastoma.
Tsubota S; Kishida S; Shimamura T; Ohira M; Yamashita S; Cao D; Kiyonari S; Ushijima T; Kadomatsu K
Cancer Res; 2017 Oct; 77(19):5259-5271. PubMed ID: 28807939
[TBL] [Abstract] [Full Text] [Related]
13. mycN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract] [Full Text] [Related]
14. Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.
Welinder C; Pawłowski K; Szasz AM; Yakovleva M; Sugihara Y; Malm J; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Rezeli M; Laurell T; Wieslander E; Marko-Varga G
PLoS One; 2017; 12(4):e0176167. PubMed ID: 28445515
[TBL] [Abstract] [Full Text] [Related]
15. TIAM1 variants improve clinical outcome in neuroblastoma.
Sanmartín E; Yáñez Y; Fornés-Ferrer V; Zugaza JL; Cañete A; Castel V; Font de Mora J
Oncotarget; 2017 Jul; 8(28):45286-45297. PubMed ID: 28423360
[TBL] [Abstract] [Full Text] [Related]
16. Medulloblastoma: Molecular Classification-Based Personal Therapeutics.
Archer TC; Mahoney EL; Pomeroy SL
Neurotherapeutics; 2017 Apr; 14(2):265-273. PubMed ID: 28386677
[TBL] [Abstract] [Full Text] [Related]
17. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
Melaiu O; Mina M; Chierici M; Boldrini R; Jurman G; Romania P; D'Alicandro V; Benedetti MC; Castellano A; Liu T; Furlanello C; Locatelli F; Fruci D
Clin Cancer Res; 2017 Aug; 23(15):4462-4472. PubMed ID: 28270499
[No Abstract] [Full Text] [Related]
18. The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Craveiro RB; Ehrhardt M; Velz J; Olschewski M; Goetz B; Pietsch T; Dilloo D
Oncotarget; 2017 Jul; 8(29):46915-46927. PubMed ID: 28159923
[TBL] [Abstract] [Full Text] [Related]
19. CD133
Garg N; Bakhshinyan D; Venugopal C; Mahendram S; Rosa DA; Vijayakumar T; Manoranjan B; Hallett R; McFarlane N; Delaney KH; Kwiecien JM; Arpin CC; Lai PS; Gómez-Biagi RF; Ali AM; de Araujo ED; Ajani OA; Hassell JA; Gunning PT; Singh SK
Oncogene; 2017 Feb; 36(5):606-617. PubMed ID: 27775079
[TBL] [Abstract] [Full Text] [Related]
20. mycN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
[TBL] [Abstract] [Full Text] [Related]
[Next]
